Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 96T |
|---|---|
| Brand | ProteoGenix |
| Product type | Elisa assay kits |
| Product name | Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit |
|---|---|
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stocks, 3-5 weeks if production is needed |
| Storage condition | 4°C for short term (1 week), store at -20°C to -80°C for long term(1 year); Avoid repeated freeze-thaw cycles |
| Brand | ProteoGenix |
| Note | For research use only. |
| Immunogen | RBD |
| Assay type | Quantitative |
| Detection method | Colorimetric |
| Recovery | 80-120% |
The Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit is a highly sensitive and specific tool for detecting and quantifying mouse immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This kit is designed to aid in the research of potential therapeutic targets for the treatment and prevention of COVID-19, caused by SARS-CoV-2.
The Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit is composed of several key components, including a 96-well microplate coated with recombinant RBD protein, mouse IgG standard, and enzyme-linked detection antibodies. The microplate is coated with the RBD protein, which is the key component of the SARS-CoV-2 spike protein responsible for binding to the human angiotensin-converting enzyme 2 (ACE2) receptor. The mouse IgG standard is used to generate a standard curve for the quantification of IgG antibodies in the sample. The enzyme-linked detection antibodies are specific for mouse IgG and are conjugated to a colorimetric enzyme for detection.
The Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit utilizes the principle of enzyme-linked immunosorbent assay (ELISA) to detect and quantify mouse IgG antibodies against the RBD of SARS-CoV-2. In this assay, the RBD-coated microplate is incubated with the sample containing mouse IgG antibodies. Any antibodies present in the sample will bind to the immobilized RBD protein. After washing away any unbound components, the enzyme-linked detection antibodies are added. These antibodies will bind specifically to the mouse IgG antibodies that are bound to the RBD protein. Finally, a substrate solution is added, and the color change is measured spectrophotometrically. The intensity of the color is directly proportional to the amount of mouse IgG antibodies present in the sample.
The Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit has multiple applications in the research of potential therapeutic targets for COVID-19. It can be used to detect and quantify mouse IgG antibodies in serum, plasma, and other biological samples. This allows for the screening of potential therapeutic agents that may induce the production of these antibodies, which could potentially neutralize the virus and prevent infection. Additionally, this kit can aid in the evaluation of vaccine candidates by measuring the antibody response in animal models.
Furthermore, the Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit can be used in epidemiological studies to determine the prevalence of SARS-CoV-2 infection in mouse populations. This information can be valuable in understanding the potential for mouse-to-human transmission of the virus and in the development of animal models for COVID-19 research.
In summary, the Anti-SARS-CoV-2 RBD Mouse IgG ELISA Kit is a valuable tool for the research of potential therapeutic targets for COVID-19. Its sensitive and specific detection of mouse IgG antibodies against the RBD of SARS-CoV-2 makes it a useful tool for screening potential therapeutic agents and evaluating vaccine candidates. Furthermore, its application in epidemiological studies can provide important insights into the prevalence and transmission of the virus.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.